Anika Therapeutics (ANIK) together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair.
Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body.
The company offers orthobiologics products for providing relief from the pain of osteoarthritis, and regenerating damaged tissue, such as cartilage defects; ORTHOVISC for the treatment of osteoarthritis of the knee and various joints; ORTHOVISC mini for the treatment of osteoarthritis in small joints; and MONOVISC, a single injection product used for the treatment of osteoarthritis in various joints.
It also provides wound care products that comprise Hyalograft 3D for the regeneration of skin; and Hyalomatrix for the treatment of burns and ulcers.
In addition, the company offers AMVISC, AMVISC Plus, STAARVISC-II, Optivisc, and AnikaVisc which are injectable HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation.
Further, it provides INCERT, a HA based product for the prevention of post-surgical adhesions; Hyalobarrier and Hyalobarrier Endo, which are post operative adhesion barriers for abdominal indications; and HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis.
Additionally, the company offers Merogel, a product used for the treatment of ear, nose, and throat disorders; and provides dermal fillers for facial wrinkles and scar remediation under the ELEVESS and HYDRELLE brand names. It markets its products directly, as well as through a network of distributors primarily in the United States and Europe.
The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Information provided by Capital IQ.
, 3:30 pm - Track One